SCHEMBL2763137

SCHEMBL2763137

CNc1nc(C#N)cc(-c2ccc(C)o2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.45
HPGD P15428 10/20 0.45
KDM4E B2RXH2 10/20 0.45
MAPT P10636 9/20 0.45
GAA P10253 9/20 0.45
PKM P14618 8/20 0.45
MEN1 O00255 7/20 0.45
KMT2A Q03164 7/20 0.45
GLA P06280 6/20 0.45
ALOX12 P18054 5/20 0.45
CASP1 P29466 4/20 0.45
HSD17B10 Q99714 4/20 0.45
CASP7 P55210 3/20 0.45
ALOX15 P16050 3/20 0.45
LMNA P02545 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
HTT P42858 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ADORA2A P29274 2/20 0.44
ADORA1 P30542 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762972 0.82 ALDH1A1 (0.49) ALDH1A1HPGDKDM4EMAPTGAA
SCHEMBL930995 0.79 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EMAPTGAA
SCHEMBL928465 0.78 ADORA2A (0.46) ALDH1A1HPGDKDM4EMAPTGAA
SCHEMBL929564 0.77 ALDH1A1 (0.45) ALDH1A1HPGDKDM4EMAPTGAA
SCHEMBL2762948 0.77 ALDH1A1 (0.45) ALDH1A1HPGDKDM4EMAPTGAA
SCHEMBL2762872 0.73 ADORA2A (0.59) ALDH1A1HPGDKDM4EMAPTPKM
SCHEMBL25083932 0.64 MAPT (0.47) ALDH1A1HPGDKDM4EMAPTGAA
SCHEMBL15935028 0.64 MYC (0.43) ALDH1A1HPGDKDM4EMAPTGAA
SCHEMBL13680700 0.62 MAP4K4 (0.41) ALDH1A1HPGDKDM4EMAPTGAA
SCHEMBL13681286 0.62 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1722798-B1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONISTS VERNALIS R&D LTD (GB) 2010-10-20 EP disclosed
US-20080182860-A1 Pyrimidine Compounds as Purine Receptor Antagonist VERNALIS (R&D) LTD. (GB) 2008-07-31 US disclosed
EP-1722798-A1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST VERNALIS (R&D) LTD (GB) 2006-11-22 EP disclosed
WO-2005079800-A1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST VERNALIS (R & D) LTD. (GB) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182860-A1 Pyrimidine Compounds as Purine Receptor Antagonist ADORA3, P2RY10, ADORA2A ALDH1A1 1455/4885HPGD 3498/4885KDM4E 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.